0:27:36 · Peter Verdalte, BNP Paribas · CagriSema, 2027 outlook
Will CagriSema get a halo from the Wegovy name, and could 2027 guidance include positive growth?
The halo is medium because CagriSema is more than semaglutide, and for 2027 management offered building blocks (pill and Bridge uptake, two launches versus Canada and China headwinds) without guiding. — Mike Doustdar
0:33:17 · Sachin, Bank of America · Bridge, UK pill
How much of US Wegovy pill growth is Bridge, how is the UK pill uptake normalising, and is the 0% midpoint the best proxy for next year?
Bridge is largely but not exclusively the 20% sequential growth, the UK pill holds about 90% share at roughly 60,000 packs a week, and management would not give 2027 numbers. — Jamie Millar, Emil, Mike Doustdar
0:36:38 · Simon Baker, Rothschild & Co. Redburn · Subscriptions, Wegovy HD
Is the subscription programme affecting script capture, and where is Wegovy HD volume coming from?
Low capture reflects partners not reporting to IQVIA rather than subscriptions, and about 80% of Wegovy HD is titration up from 2.4 mg. — Jamie Millar, Emil
0:40:36 · Martin Parker, SEB · Tri-agonists, Ozempic pill
What should we expect on adverse events from the tri-agonist readouts, and will Ozempic pill be rebranded outside the US?
Management aims for adverse events in line with existing GLP-1 therapies, and for International Operations it is focused on the Ozempic 2.0 mg launch first. — Martin Holz-Lange, Emil
0:44:50 · Matthew Weston, UBS · 2027 baseline, MASH
Is the second-half exit rate or the full-year 0% midpoint the better baseline for 2027, and will the MASH asset launch early on F3 data?
Management would not give a number and will weigh the year's pluses and minuses, and it will follow the data across F2, F3 and F4 for the MASH asset. — Mike Doustdar, Martin Holz-Lange
0:46:33 · Richard Vosser, JPMorgan · Pricing, pill rollout
What are the Ozempic price dynamics, and how do the roughly 12 additional pill markets compare with the UK?
Net price erosion of 10% to 15% a year still looks reasonable, and markets like Mexico with low treatment rates offer larger expansion potential than mature ones. — Jamie Millar, Emil
0:49:58 · Michael Lugten, Jefferies · Medicare Bridge
Would the GLP-1 franchise have grown without Bridge, and what happens as it annualises?
Without Bridge there would be less growth than the 20% sequential rise, and the category looks flat without it. — Jamie Millar
0:51:12 · James Quigley, Goldman Sachs · Guidance, CagriSema launch
What drives the wide implied Q4 range and the gross-to-net comparison, and how will CagriSema be segmented at launch?
The range is customary for a volatile growing category, with a tough Q4 comparator and Canada exclusivity loss, and management declined to detail CagriSema launch strategy beyond portfolio breadth. — Carsten, Jamie Millar
0:54:44 · Martin Breno, Nordea · Pricing, pill rollout
What are the 2027 price building blocks, and why is the pill rollout accelerating?
Ozempic net price erosion of 10% to 15% continues and Wegovy erosion was 30-35% in the quarter, while the faster pill rollout reflects stepped-up manufacturing and regulatory work. — Jamie Millar, Emil
0:57:26 · Seamus Fernandes, Guggenheim Securities · US payers
How do you get commercial payers to support obesity coverage given Bridge was the main accelerator?
Payers and employers are increasingly worried about volume rather than price, so Novo is working with them to manage cost trends while list prices fall in 2027. — Jamie Millar
1:00:32 · Kerry Holford, Berenberg · Medicare Bridge
What happens if Medicare coverage does not continue beyond the end of Bridge?
It is hard to predict, but management expects political pressure to continue coverage as more seniors use it, and Bridge is designed to document eligibility, cost and outcomes. — Jamie Millar